Dec 1, 2022
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Multiple Myeloma Outcomes Based...
132
Dec 16, 2021
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
BMT CTN 1902 NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902 MM CAR-T to Upgrade Response BMT CTN 1902 This study is...
291
Dec 10, 2021
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma...
87
Dec 11, 2020
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma...
136
Dec 1, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...
1,115
Dec 19, 2019
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...
776
Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
1,084
Dec 13, 2019
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NKTR-255 in Relapsed/Refractory Multiple...
139
Dec 13, 2019
NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory
(LUMMICAR STUDY 2) NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma...
370
Dec 11, 2019
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...
757
Dec 1, 2019
NCT03798678: Phase 1 - CB-839 HCl + Carfilzomib and Dex - Refractory MM
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma Kd This...
328
Dec 31, 2018
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...
811
Dec 19, 2018
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...
520
Dec 29, 2017
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402
CRB-402 Study of bb21217 in Multiple Myeloma Relapsed Refractory Multiple Myeloma RRMM Study CRB-402 is a 2-part, non-randomized, open...
420
Dec 16, 2017
NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT
ASCENT TRIAL Dara-KRd Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT) This study evaluates the...
432
Dec 8, 2017
NCT03314181: Phase 2 - Venetoclax, Daratumumab and Dex (+/- Bortezomib) in RRMM Multiple Myeloma
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed...
82
Dec 31, 2016
NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN
The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...
710
Dec 11, 2010
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NDMM - DFCI 10-106 DETERMINATION Trial Delayed vs Early Transplant with Revlimid Maintenance and Anti-Myeloma Triple Therapy DFCI 10-106...
1,132
Dec 9, 2010
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
STaMINA Trial BMT CTN 0702 NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma...
183